Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tear-film Lipid Layer Thickness and Ocular Aberration in MGD Treatment
NCT02618304Completed
- Sponsor
- Yonsei University
- Start
- Apr 2015
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of diquafosol in meibomian gland dysfunction (MGD), sponsored by Yonsei University. Primary endpoints: Changes of tear-film lipid layer thickness at 2 months and Changes of ocular aberration at 2 months. Started Apr 2015; status: completed.
02
Drugs
diquafosol
03
Conditions
meibomian gland dysfunction (MGD)
Beyond the preview
Go deeper on NCT02618304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02618304.